Linda Sangalli, Sahar Mirfarsi, Jill M Kramer, Elfatih Eisa, Craig S Miller
{"title":"管理灼口综合征:当前和未来的方向。","authors":"Linda Sangalli, Sahar Mirfarsi, Jill M Kramer, Elfatih Eisa, Craig S Miller","doi":"10.1007/s40265-025-02220-x","DOIUrl":null,"url":null,"abstract":"<p><p>Burning mouth syndrome (BMS) is a chronic pain condition characterized by a persistent burning sensation in the oral mucosa in the absence of visible clinical signs. Its management remains a significant clinical challenge due to the unclear and multifactorial nature of its etiopathogenesis. Differentiating between primary (idiopathic) and secondary (associated with identifiable underlying conditions) BMS is critical for guiding treatment. Current management strategies range from addressing underlying systemic or local factors to utilizing established systemic or topical pharmacologic options (such as benzodiazepines, capsaicin, anticonvulsants, antidepressants), new off-label treatments (including low-dose naltrexone), supplements (such as alpha lipoic acid and phytotherapeutics), alongside non-pharmacological approaches aimed at addressing pain symptoms and enhancing pain-coping skills (such as nerve blocks, cognitive behavioral therapy, and transcranial magnetic stimulation). This review synthesizes the current evidence supporting both established and newly investigated therapies and discusses future research directions to improve outcomes for individuals affected by this chronic pain condition. Ultimately, the best management approach should be based on the most robust evidence-based findings, tailored to the underlying etiopathogenetic mechanisms, and individualized to address patient contributing factors.</p>","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1109-1131"},"PeriodicalIF":14.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Managing Burning Mouth Syndrome: Current and Future Directions.\",\"authors\":\"Linda Sangalli, Sahar Mirfarsi, Jill M Kramer, Elfatih Eisa, Craig S Miller\",\"doi\":\"10.1007/s40265-025-02220-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Burning mouth syndrome (BMS) is a chronic pain condition characterized by a persistent burning sensation in the oral mucosa in the absence of visible clinical signs. Its management remains a significant clinical challenge due to the unclear and multifactorial nature of its etiopathogenesis. Differentiating between primary (idiopathic) and secondary (associated with identifiable underlying conditions) BMS is critical for guiding treatment. Current management strategies range from addressing underlying systemic or local factors to utilizing established systemic or topical pharmacologic options (such as benzodiazepines, capsaicin, anticonvulsants, antidepressants), new off-label treatments (including low-dose naltrexone), supplements (such as alpha lipoic acid and phytotherapeutics), alongside non-pharmacological approaches aimed at addressing pain symptoms and enhancing pain-coping skills (such as nerve blocks, cognitive behavioral therapy, and transcranial magnetic stimulation). This review synthesizes the current evidence supporting both established and newly investigated therapies and discusses future research directions to improve outcomes for individuals affected by this chronic pain condition. Ultimately, the best management approach should be based on the most robust evidence-based findings, tailored to the underlying etiopathogenetic mechanisms, and individualized to address patient contributing factors.</p>\",\"PeriodicalId\":11482,\"journal\":{\"name\":\"Drugs\",\"volume\":\" \",\"pages\":\"1109-1131\"},\"PeriodicalIF\":14.4000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40265-025-02220-x\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40265-025-02220-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Managing Burning Mouth Syndrome: Current and Future Directions.
Burning mouth syndrome (BMS) is a chronic pain condition characterized by a persistent burning sensation in the oral mucosa in the absence of visible clinical signs. Its management remains a significant clinical challenge due to the unclear and multifactorial nature of its etiopathogenesis. Differentiating between primary (idiopathic) and secondary (associated with identifiable underlying conditions) BMS is critical for guiding treatment. Current management strategies range from addressing underlying systemic or local factors to utilizing established systemic or topical pharmacologic options (such as benzodiazepines, capsaicin, anticonvulsants, antidepressants), new off-label treatments (including low-dose naltrexone), supplements (such as alpha lipoic acid and phytotherapeutics), alongside non-pharmacological approaches aimed at addressing pain symptoms and enhancing pain-coping skills (such as nerve blocks, cognitive behavioral therapy, and transcranial magnetic stimulation). This review synthesizes the current evidence supporting both established and newly investigated therapies and discusses future research directions to improve outcomes for individuals affected by this chronic pain condition. Ultimately, the best management approach should be based on the most robust evidence-based findings, tailored to the underlying etiopathogenetic mechanisms, and individualized to address patient contributing factors.
期刊介绍:
Drugs is a journal that aims to enhance pharmacotherapy by publishing review and original research articles on key aspects of clinical pharmacology and therapeutics. The journal includes:
Leading/current opinion articles providing an overview of contentious or emerging issues.
Definitive reviews of drugs and drug classes, and their place in disease management.
Therapy in Practice articles including recommendations for specific clinical situations.
High-quality, well designed, original clinical research.
Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs.
AdisInsight Reports summarising development at first global approval.
Moreover, the journal offers additional digital features such as animated abstracts, video abstracts, instructional videos, and podcasts to increase visibility and educational value. Plain language summaries accompany articles to assist readers with some knowledge of the field in understanding important medical advances.